MovDisordV3, Main, Exploration, bibRecord, 004A05

Parkinsonism, dystonia, and hemiatrophy

Identifieur interne : 004A05 ( Main/Exploration ); précédent : 004A04; suivant : 004A06

Parkinsonism, dystonia, and hemiatrophy

Auteurs : Paul E. Greene [États-Unis] ; Susan B. Bressman [États-Unis] ; Blair Ford [États-Unis] ; Keith Hyland [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 2000-05.

RBID : ISTEX:D19F4BA3464DEF576C9653CD00D556CC7DC6DFB8

Descripteurs français

Pascal (Inist)
- Association morbide, Dopamine, Dystonie, Etiopathogénie, Etude cas, Homme, Hémiatrophie, Parkinsonisme, Unilatéral, Voie nigrostriatale.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Adolescent, Antiparkinson Agents (administration & dosage), Carbidopa (administration & dosage), Case study, Caudate Nucleus (pathology), Child, Child, Preschool, Concomitant disease, Dominance, Cerebral (genetics), Dopamine, Dopa‐responsive dystonia, Drug Therapy, Combination, Dystonia, Dystonia (diagnosis), Dystonia (drug therapy), Dystonia (genetics), Etiopathogenesis, Hemiatrophy, Hemiparkinson–hemiatrophy syndrome, Human, Humans, Infant, Infant, Newborn, Levodopa (administration & dosage), Magnetic Resonance Imaging, Muscular Atrophy (diagnosis), Muscular Atrophy (drug therapy), Muscular Atrophy (genetics), Neurologic Examination, Nigrostriatal pathway, Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson Disease (genetics), Parkinsonism, Phenylalanine loading challenge, Putamen (pathology), Treatment Outcome, Unilateral.
MESH :
- chemical , administration & dosage : Antiparkinson Agents, Carbidopa, Levodopa.
- diagnosis : Dystonia, Muscular Atrophy, Parkinson Disease.
- drug therapy : Dystonia, Muscular Atrophy, Parkinson Disease.
- genetics : Dominance, Cerebral, Dystonia, Muscular Atrophy, Parkinson Disease.
- pathology : Caudate Nucleus, Putamen.
- Adolescent, Child, Child, Preschool, Drug Therapy, Combination, Humans, Infant, Infant, Newborn, Magnetic Resonance Imaging, Neurologic Examination, Treatment Outcome.

Abstract

Hemiatrophy has been reported in association with a variety of neurologic conditions, including parkinsonism. Patients with the hemiparkinson–hemiatrophy syndrome (HP–HA) have asymmetric parkinsonism with limb atrophy on the more affected side. Several authors have suggested that asymmetric brain damage early in life results in both atrophy and parkinsonism. Dopa‐responsive dystonia (DRD) is a disease in which a deficiency of tetrahydrobiopterin, or, less commonly, of tyrosine hydroxylase, results in levodopa‐responsive dystonia with parkinson features in children. We have recently identified four patients with DRD who had asymmetric dystonia and limb atrophy on the more affected side. Based on these patients, we suggest that a deficiency of the nigrostriatal dopamine system may, by itself, be sufficient to cause body atrophy and may underlie the limb atrophy in both DRD and HP–HA.

Url:

https://api.istex.fr/document/D19F4BA3464DEF576C9653CD00D556CC7DC6DFB8/fulltext/pdf

DOI: 10.1002/1531-8257(200005)15:3<537::AID-MDS1018>3.0.CO;2-3

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Parkinsonism, dystonia, and hemiatrophy</title>
<author><name sortKey="Greene, Paul E" sort="Greene, Paul E" uniqKey="Greene P" first="Paul E." last="Greene">Paul E. Greene</name>
</author>
<author><name sortKey="Bressman, Susan B" sort="Bressman, Susan B" uniqKey="Bressman S" first="Susan B." last="Bressman">Susan B. Bressman</name>
</author>
<author><name sortKey="Ford, Blair" sort="Ford, Blair" uniqKey="Ford B" first="Blair" last="Ford">Blair Ford</name>
</author>
<author><name sortKey="Hyland, Keith" sort="Hyland, Keith" uniqKey="Hyland K" first="Keith" last="Hyland">Keith Hyland</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:D19F4BA3464DEF576C9653CD00D556CC7DC6DFB8</idno>
<date when="2000" year="2000">2000</date>
<idno type="doi">10.1002/1531-8257(200005)15:3<537::AID-MDS1018>3.0.CO;2-3</idno>
<idno type="url">https://api.istex.fr/document/D19F4BA3464DEF576C9653CD00D556CC7DC6DFB8/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002992</idno>
<idno type="wicri:Area/Istex/Curation">002992</idno>
<idno type="wicri:Area/Istex/Checkpoint">003205</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Greene P:parkinsonism:dystonia:and</idno>
<idno type="wicri:Area/Main/Merge">007302</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:00-0270531</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002C01</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000120</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002B50</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Greene P:parkinsonism:dystonia:and</idno>
<idno type="wicri:Area/Main/Merge">007542</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:10830421</idno>
<idno type="wicri:Area/PubMed/Corpus">003F71</idno>
<idno type="wicri:Area/PubMed/Curation">003F71</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003F17</idno>
<idno type="wicri:Area/Ncbi/Merge">000280</idno>
<idno type="wicri:Area/Ncbi/Curation">000280</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000280</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Greene P:parkinsonism:dystonia:and</idno>
<idno type="wicri:Area/Main/Merge">007060</idno>
<idno type="wicri:Area/Main/Curation">004A05</idno>
<idno type="wicri:Area/Main/Exploration">004A05</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Parkinsonism, dystonia, and hemiatrophy</title>
<author><name sortKey="Greene, Paul E" sort="Greene, Paul E" uniqKey="Greene P" first="Paul E." last="Greene">Paul E. Greene</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Dystonia Clinical Research Center, Neurological Institute, Columbia‐Presbyterian Medical Center, New York, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bressman, Susan B" sort="Bressman, Susan B" uniqKey="Bressman S" first="Susan B." last="Bressman">Susan B. Bressman</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Dystonia Clinical Research Center, Neurological Institute, Columbia‐Presbyterian Medical Center, New York, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ford, Blair" sort="Ford, Blair" uniqKey="Ford B" first="Blair" last="Ford">Blair Ford</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Dystonia Clinical Research Center, Neurological Institute, Columbia‐Presbyterian Medical Center, New York, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hyland, Keith" sort="Hyland, Keith" uniqKey="Hyland K" first="Keith" last="Hyland">Keith Hyland</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Kimberly H. Courtwright and Joseph W. Summers Institute of Metabolic Disease, Baylor University Medical Center, Dallas, Texas</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2000-05">2000-05</date>
<biblScope unit="vol">15</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="537">537</biblScope>
<biblScope unit="page" to="541">541</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">D19F4BA3464DEF576C9653CD00D556CC7DC6DFB8</idno>
<idno type="DOI">10.1002/1531-8257(200005)15:3<537::AID-MDS1018>3.0.CO;2-3</idno>
<idno type="ArticleID">MDS1018</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Carbidopa (administration & dosage)</term>
<term>Case study</term>
<term>Caudate Nucleus (pathology)</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Concomitant disease</term>
<term>Dominance, Cerebral (genetics)</term>
<term>Dopamine</term>
<term>Dopa‐responsive dystonia</term>
<term>Drug Therapy, Combination</term>
<term>Dystonia</term>
<term>Dystonia (diagnosis)</term>
<term>Dystonia (drug therapy)</term>
<term>Dystonia (genetics)</term>
<term>Etiopathogenesis</term>
<term>Hemiatrophy</term>
<term>Hemiparkinson–hemiatrophy syndrome</term>
<term>Human</term>
<term>Humans</term>
<term>Infant</term>
<term>Infant, Newborn</term>
<term>Levodopa (administration & dosage)</term>
<term>Magnetic Resonance Imaging</term>
<term>Muscular Atrophy (diagnosis)</term>
<term>Muscular Atrophy (drug therapy)</term>
<term>Muscular Atrophy (genetics)</term>
<term>Neurologic Examination</term>
<term>Nigrostriatal pathway</term>
<term>Parkinson Disease (diagnosis)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (genetics)</term>
<term>Parkinsonism</term>
<term>Phenylalanine loading challenge</term>
<term>Putamen (pathology)</term>
<term>Treatment Outcome</term>
<term>Unilateral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Carbidopa</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dystonia</term>
<term>Muscular Atrophy</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dystonia</term>
<term>Muscular Atrophy</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Dominance, Cerebral</term>
<term>Dystonia</term>
<term>Muscular Atrophy</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Caudate Nucleus</term>
<term>Putamen</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Drug Therapy, Combination</term>
<term>Humans</term>
<term>Infant</term>
<term>Infant, Newborn</term>
<term>Magnetic Resonance Imaging</term>
<term>Neurologic Examination</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Association morbide</term>
<term>Dopamine</term>
<term>Dystonie</term>
<term>Etiopathogénie</term>
<term>Etude cas</term>
<term>Homme</term>
<term>Hémiatrophie</term>
<term>Parkinsonisme</term>
<term>Unilatéral</term>
<term>Voie nigrostriatale</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Hemiatrophy has been reported in association with a variety of neurologic conditions, including parkinsonism. Patients with the hemiparkinson–hemiatrophy syndrome (HP–HA) have asymmetric parkinsonism with limb atrophy on the more affected side. Several authors have suggested that asymmetric brain damage early in life results in both atrophy and parkinsonism. Dopa‐responsive dystonia (DRD) is a disease in which a deficiency of tetrahydrobiopterin, or, less commonly, of tyrosine hydroxylase, results in levodopa‐responsive dystonia with parkinson features in children. We have recently identified four patients with DRD who had asymmetric dystonia and limb atrophy on the more affected side. Based on these patients, we suggest that a deficiency of the nigrostriatal dopamine system may, by itself, be sufficient to cause body atrophy and may underlie the limb atrophy in both DRD and HP–HA.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Texas</li>
<li>État de New York</li>
</region>
</list>
<tree><country name="États-Unis"><region name="État de New York"><name sortKey="Greene, Paul E" sort="Greene, Paul E" uniqKey="Greene P" first="Paul E." last="Greene">Paul E. Greene</name>
</region>
<name sortKey="Bressman, Susan B" sort="Bressman, Susan B" uniqKey="Bressman S" first="Susan B." last="Bressman">Susan B. Bressman</name>
<name sortKey="Ford, Blair" sort="Ford, Blair" uniqKey="Ford B" first="Blair" last="Ford">Blair Ford</name>
<name sortKey="Hyland, Keith" sort="Hyland, Keith" uniqKey="Hyland K" first="Keith" last="Hyland">Keith Hyland</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004A05 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004A05 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:D19F4BA3464DEF576C9653CD00D556CC7DC6DFB8
   |texte=   Parkinsonism, dystonia, and hemiatrophy
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Parkinsonism, dystonia, and hemiatrophy

Parkinsonism, dystonia, and hemiatrophy

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.